Post hoc analysis of Protocol T extension (116 eyes, diabetic macular oedema): hard exudate volume fell through week 104 after anti-VEGF then stabilised; early greater falls with aflibercept and ranibizumab vs bevacizumab vanished by 2 years. No link to 5-year VA.
Secondary analysisn = 116 eyes
Pak et al. Long term evolutions of hard exudates after anti-VEGF therapy for diabetic macular oedema